diabetics
Novartis Diabetes Drug Galvus, EU-Approved for Type 2 Diabetes
Filed in archive News , Treatment by Gloria Gamat on October 1, 2007
While Novartis AG is still waiting the FDA approval for its type 2 diabetes drug Galvus, the EU has already granted marketing approval for the said drug.

Novartis Diabetes Drug Galvus, EU-Approved for Type 2 Diabetes


Galvus (vildagliptin) is a once-daily oral treatment for type 2 diabetes: a DPP-4 inhibitor that works by targeting the dysfunction in the pancreatic islets that causes high blood-sugar levels in people with Type 2 diabetes.

The FDA has requested additional clinical trials of once-daily Galvus, an oral treatment. Novartis, based in Basel, Switzerland, said talks with the FDA are continuing.

Novartis has high hopes for the drug, which it has said has the potential to eventually generate revenue of $1 billion or more, making Galvus a critical development drug, alongside Tekturna, a recently approved pill to control high blood pressure.


Source: Wall Street Journal, Novartis AG (pdf file)


Permalink: Novartis Diabetes Drug Galvus, EU-Approved for Type 2 Diabetes
Tags: Galvus  vildagliptin  type  2  diabetes  Novartis  AG    galvus  type+diabetes 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/94664
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Novartis Diabetes Drug Galvus, EU-Approved for Type 2 Diabetes:

  • Currently 7.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 7.50 out of 4 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!